Parathyroid Hormone-Related Changes of Bone Structure.


Journal

Physiological research
ISSN: 1802-9973
Titre abrégé: Physiol Res
Pays: Czech Republic
ID NLM: 9112413

Informations de publication

Date de publication:
30 11 2021
Historique:
entrez: 17 12 2021
pubmed: 18 12 2021
medline: 11 3 2022
Statut: ppublish

Résumé

Parathyroid hormone (PTH) increases the release of serum calcium through osteoclasts, which leads to bone resorption. Primary, PTH stimulates osteoblasts leading to increase RANKL (receptor activator for nuclear factor kappa-B ligand) expression and thus differentiation of osteoclasts. In kidneys, PTH increases calcium and decrease phosphate reabsorption. In kidneys, PTH stimulates 1alpha-hydroxylase to synthesize active vitamin D. Primary hyperparathyroidism (PHPT) is characterized by skeletal or renal complications. Nowadays, the classical form of PHPT is less seen and asymptomatic or subclinical (oligo symptomatic) forms are more frequent. Previously, it was thought that cortical bone is preferably affected by PHPT and that predispose bones to fracture at sites with a higher amount of cortical bone. However, an increased risk of vertebral fractures has been found by most of the studies showing that also trabecular bone is affected. Bone Mass measurement (BMD) at all skeletal sites is advised, but another specific tool for fracture assessment is needed. Trabecular bone score (TBS), an indirect measure of trabecular bone, maybe a useful method to estimate fracture risk. TBS is associated with vertebral fractures in PHPT regardless of BMD, age, BMI and gender. Furthermore, there is an association between TBS and high resolution peripheral quantitative computed tomography (HR-pQCT) parameters in the trabecular and cortical compartment. However, studies considering the effect of PHPT treatment on TBS are more conflicting. Secondary hyperparathyroidism caused by vitamin D deficiency was associated with impaired bone microarchitecture in all age categories, as measured by TBS and Hr-pQCT with further improvement after treatment with vitamin D.

Identifiants

pubmed: 34918524
pii: 934779
doi: 10.33549/physiolres.934779
pmc: PMC8884379

Substances chimiques

Parathyroid Hormone 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

S3-S11

Références

Bone. 2013 Nov;57(1):232-6
pubmed: 23948677
J Clin Endocrinol Metab. 2014 Oct;99(10):3570-9
pubmed: 25162666
Arq Bras Endocrinol Metabol. 2014 Jul;58(5):553-61
pubmed: 25166047
J Bone Miner Res. 2010 Feb;25(2):305-12
pubmed: 19594303
J Bone Miner Res. 2010 Sep;25(9):1941-7
pubmed: 20499376
J Clin Endocrinol Metab. 2009 Jul;94(7):2306-12
pubmed: 19401378
J Intern Med. 2016 Nov;280(5):496-508
pubmed: 27196563
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1512-1521
pubmed: 29373705
J Bone Miner Res. 2006 Mar;21(3):366-73
pubmed: 16491283
Endocrinol Metab Clin North Am. 2018 Dec;47(4):743-758
pubmed: 30390810
Osteoporos Int. 2016 Aug;27(8):2477-88
pubmed: 27010646
J Clin Endocrinol Metab. 2013 May;98(5):1963-70
pubmed: 23526463
Horm Metab Res. 2018 Aug;50(8):609-614
pubmed: 29954010
Bone. 2016 May;86:58-67
pubmed: 26924718
Osteoporos Int. 2013 Jan;24(1):77-85
pubmed: 23070481
J Bone Miner Res. 1999 Oct;14(10):1700-7
pubmed: 10491217
Int J Endocrinol. 2014;2014:820615
pubmed: 25050121
Eur J Endocrinol. 2013 Jun 29;169(2):155-62
pubmed: 23682095
Science. 1991 Nov 15;254(5034):1024-6
pubmed: 1658941
J Clin Densitom. 2018 Jul - Sep;21(3):453-458
pubmed: 29657024
J Bone Miner Res. 1995 Sep;10(9):1393-9
pubmed: 7502712
Rev Endocr Metab Disord. 2006 Jun;7(1-2):113-21
pubmed: 17043762
Calcif Tissue Int. 2019 Feb;104(2):160-170
pubmed: 30293198
Bone. 2007 Jun;40(6):1453-61
pubmed: 17376756
J Clin Endocrinol Metab. 2015 Apr;100(4):1359-67
pubmed: 25636048
J Bone Miner Res. 2011 Nov;26(11):2762-9
pubmed: 21887701
J Clin Endocrinol Metab. 2008 Sep;93(9):3462-70
pubmed: 18544625
J Bone Miner Res. 2016 May;31(5):940-8
pubmed: 26498132
Bone. 2013 Mar;53(1):154-9
pubmed: 23228370
Eur J Endocrinol. 2006 Sep;155(3):415-20
pubmed: 16914595
J Clin Endocrinol Metab. 2014 Oct;99(10):3561-9
pubmed: 25162665
J Biol Chem. 2007 Nov 9;282(45):33086-97
pubmed: 17690103
J Clin Endocrinol Metab. 1999 May;84(5):1562-6
pubmed: 10323380
J Bone Miner Res. 2012 May;27(5):1150-8
pubmed: 22228118
Endocrine. 2017 Nov;58(2):380-385
pubmed: 28900835
J Bone Miner Res. 1990 Oct;5(10):1043-53
pubmed: 2080716
Osteoporos Int. 2017 Jan;28(1):1-19
pubmed: 27613721
Osteoporos Int. 2016 Jan;27(1):39-48
pubmed: 26252975
N Engl J Med. 1999 Oct 21;341(17):1249-55
pubmed: 10528034
Horm Metab Res. 2019 Mar;51(3):186-190
pubmed: 30861565
Somatic Cell Genet. 1983 Sep;9(5):609-16
pubmed: 6353628
Bone. 1995 Jan;16(1):109-17
pubmed: 7742068
J Bone Miner Res. 2013 May;28(5):1029-40
pubmed: 23225022
J Clin Endocrinol Metab. 2013 Feb;98(2):602-9
pubmed: 23341489

Auteurs

M Kužma (M)

5th department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital Bratislava, Bratislava, Slovakia. martin.kuzma@fmed.uniba.sk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH